{
    "clinical_study": {
        "@rank": "20015", 
        "arm_group": {
            "arm_group_label": "BI 853520", 
            "arm_group_type": "Experimental", 
            "description": "BI 853520 once daily in a dose escalation schedule"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this trial is to explore the safety and tolerability of BI 853520\n      monotherapy and determine the maximum tolerated dose (MTD) for Japanese and Taiwanese\n      patients with advanced or metastatic solid tumours.\n\n      Secondary objective is collection of preliminary data on anti-tumour efficacy"
        }, 
        "brief_title": "A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Patients with a confirmed diagnosis of advanced, measurable or evaluable,\n             non-resectable and/or metastatic non-hematologic malignancy, which has shown to be\n             progressive in the last 6 months\n\n          -  Patients who have failed conventional treatment or for whom no therapy of proven\n             efficacy exists or who are not amenable to established treatment options\n\n          -  Recovery from reversible toxicities (alopecia excluded) of prior anti-cancer\n             therapies  (Common Terminology Criteria for Adverse Events grade <2)\n\n          -  Age >= 20 years\n\n          -  Written informed consent in accordance with International Conference on\n             Harmonisation/Good Clinical Practice  (ICH/GCP) and local legislation\n\n          -  Eastern Cooperative Oncology Group (ECOG), performance score 0-1\n\n        Exclusion criteria:\n\n          -  Serious concomitant non-oncological disease/illness\n\n          -  Active/symptomatic brain metastases\n\n          -  Second malignancy\n\n          -  Pregnancy or breastfeeding\n\n          -  Women or men who are sexually active and unwilling to use a medically acceptable\n             method of contraception.\n\n          -  Treatment with cytotoxic anti-cancer-therapies or investigational drugs within four\n             weeks of the first treatment with the study medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01905111", 
            "org_study_id": "1300.15"
        }, 
        "intervention": {
            "arm_group_label": "BI 853520", 
            "description": "BI 853520 once daily in a dose escalation schedule", 
            "intervention_name": "BI 853520", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kashiwa-shi, Chiba", 
                        "country": "Japan"
                    }, 
                    "name": "1300.15.81001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "1300.15.88601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Taiwan : Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determination of the MTD. It will be defined by the occurrence of dose-limiting toxicities (DLT) during the first treatment cycle of each patient", 
            "safety_issue": "No", 
            "time_frame": "After the first 28 days of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01905111"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks until end of study participation, assessed up to 12 months"
            }, 
            {
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks until end of study participation, assessed up to 12 months"
            }, 
            {
                "measure": "Duration of disease control", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks until end of study participation, assessed up to 12 months"
            }, 
            {
                "measure": "Tumour shrinkage (in millimetre) defined as the difference between the minimum post-baseline sum of longest diameters of target lesions and the baseline sum of longest diameters of the same set of target lesions", 
                "safety_issue": "No", 
                "time_frame": "Every 8 weeks until end of study participation, assessed up to 12 months"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}